Peptavo is Accredited for 20 CME hours.Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
Peptavo is Accredited for 20 CME hours.Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
Get volume discounts if you are getting 3 or more clinicians certified
Book a Call
Peptide therapy documentation should let a stranger reconstruct every decision: why the patient needed the peptide, what product it was and where it came from, what the patient agreed to, and how you tracked the result. Here is what to chart at intake, at each dose, and at every follow-up.
Good peptide therapy documentation lets someone who has never met the patient reconstruct every decision from the chart alone: the indication, the product and its regulatory status, the source and lot, the consent, the dose, and the monitoring that justified continuing or stopping. Most peptides are prescribed off label or compounded, so the chart carries more weight than it does for an on-label prescription.
The people who read that chart are a board investigator after a complaint, a plaintiff's expert, a pharmacist checking a prescription, and you, months later, trying to remember why the dose changed. This guide covers what each of them needs to find, in the order the records are created.
Status as of November 13, 2026. This guide is general education for clinicians, not legal or medical advice, and following it does not guarantee any outcome with a board, a payer, or a court. It covers federal rules and general practice. Charting standards, retention periods, and scope rules are set by each state and by your malpractice carrier, so have a health care attorney licensed in your state review your forms and charting policies before you adopt them.
Three things send someone to a peptide chart. A patient complains to the medical board, often about cost or an outcome rather than safety. A pharmacy or regulator asks about a compounded prescription. Or a product is recalled, and the clinic has to find every patient who received it.
The last one is the case clinics forget. In 2012, contaminated steroid injections from the New England Compounding Center caused a fungal meningitis outbreak that the CDC linked to 753 cases and 64 deaths across 20 states. Public health teams contacted more than 14,000 exposed patients in 23 states, working from the compounder's distribution lists for the implicated lots and the clinics' own records of who received each injection. A clinic that charts "peptide injection given" without a lot number cannot answer that call.
The chart should name a specific indication tied to findings. "Wellness" or "anti-aging" gives a reviewer nothing to measure the prescription against. Record the symptoms, the history, the baseline labs or measurements, and a goal you can check later, such as a body composition target, a lab range, or a functional score.
Record the contraindication screen as a finding, including negatives. For growth hormone secretagogues, the course Dr. Jesse Morse, MD teaches requires a documented five-year cancer-free history before the first prescription, because IGF-1 elevation is a growth signal. A chart that shows the question was asked and answered is far stronger than one that is silent.
If approved therapies were considered and set aside, say why. That single sentence is what separates a reasoned off-label choice from a menu order.
Write down what kind of product it is, because each kind has its own rules.
| Product | What the chart should record |
|---|---|
| FDA-approved peptide drug | The drug, that it is approved, and whether this use is on or off label. Our guide to off-label peptide prescribing covers the evidence record |
| Compounded by a 503A pharmacy | The pharmacy and its license, the patient-specific prescription, and the qualifying status of the bulk substance on the date you prescribed |
| Office stock from a 503B outsourcing facility | The facility, its FDA registration, the lot number, and the beyond-use date from the label |
| Research use only product | Nothing, because it has no lawful prescribing pathway. See our guide to research use only peptides |
A 503A pharmacy compounds for an identified patient on a valid prescription, so a 503A vial in the clinic belongs to the named patient. Stock you hold to administer to many patients has to come from a 503B outsourcing facility. Our guide to 503A vs. 503B pharmacies sets out the difference.
When the compounded product matches a commercially available approved drug, the prescription should carry your reasoning. FDA's 503A guidance on compounded drugs that are essentially copies treats a product with the same active ingredient, strength, and route as a copy unless the prescriber determines and documents on the prescription a change that produces a significant difference for the identified patient, such as leaving out an inactive ingredient the patient is allergic to. FDA says a lower price does not qualify.
File the pharmacy's certificate of analysis with the order, or note where it is stored. Our guide to reading a certificate of analysis covers what to check on it.
The AMA Code of Medical Ethics, Opinion 2.1.1, tells physicians to "document the informed consent conversation and the patient's (or surrogate's) decision in the medical record in some manner." That allows any written record, but for off-label and compounded peptides the course teaches a signed and dated form, because verbal consent leaves no proof of what the patient was told.
The form and the note should cover the product's approval status, that the use is off label where it is, what the evidence shows and where it is thin, the known and theoretical risks, the alternatives including doing nothing, the sourcing pathway, the monitoring plan, the criteria for stopping, and the cost. Our peptide therapy consent kit includes an off-label and compounded product disclosure to adapt with your counsel.
Cost belongs in the record for a federal reason as well. Under the No Surprises Act, a provider must give uninsured and self-pay patients a good faith estimate when they schedule a service at least three business days ahead or ask for one (45 CFR 149.610). It is due within one business day of scheduling for a service three to nine business days out, and within three business days for one ten or more days out or after a request. A patient with insurance who chooses not to file a claim counts as self-pay, which covers many peptide programs. The estimate must be kept the same way as the medical record, a copy must be available for six years, and one estimate can cover a recurring program for no more than 12 months.
Chart the compound, concentration, dose, route, frequency, planned duration, and start date. Write the dose in mass units, micrograms or milligrams, alongside the volume drawn. "Units" on an insulin syringe measure volume, so "10 units" means a different amount of drug in every concentration, a common source of confusion in peptide dosing.
For doses given in the clinic, keep an administration record for each one: date and time, product, lot number, beyond-use date, dose and volume, site, who gave it, and how the patient did afterward. For doses the patient gives at home, chart the teaching: injection technique, storage, the beyond-use date, and sharps disposal. Our guide to storing and handling compounded peptides covers what the clinic has to track once a vial is reconstituted.
Each follow-up note should compare the result with the goal set at intake: the response, side effects, lab results, and adherence. Every dose change needs its reason in the same note. A dose that rises across three visits with no stated reason is the pattern a reviewer notices first.
Tie refills to follow-up. A refill approved without a visit or a lab review on schedule should say why. When you stop a peptide, chart the reason and whether it was a stop criterion from the consent.
Messages between visits count. Portal messages, texts, and calls that change the plan or report a side effect belong in the chart, not on a phone.
Chart the event, the product and lot, your assessment, and what you did. Then report it. FDA encourages health professionals to report adverse events and quality defects with compounded drugs to MedWatch on Form 3500, which has a box marking the product as compounded. Reports are welcome even when causation is uncertain, and several reports tied to one pharmacy are how FDA spots a quality problem. Tell the dispensing pharmacy too, and note both reports in the chart.
For a remote visit, record where the patient was physically located, because that state's licensing and prescribing rules apply. Record how you examined the patient and what you reviewed. Our guide to telehealth peptide prescribing covers the licensure rules.
Nurse practitioners and physician assistants should chart within the terms of their practice agreement and record any collaboration or co-signature it requires. Where the agreement says nothing about off-label or compounded drugs, fix the agreement before the prescription. The nurse practitioner guide covers state practice levels.
Outside specific federal programs, federal law sets no general retention period for physician records; your state does, and periods differ for adults and minors. Keep consent forms, administration records, certificates of analysis, and good faith estimates for at least as long as the chart itself, and confirm the longer of your state rule and your malpractice carrier's recommendation.
The Peptavo Peptide Therapy Course teaches documentation alongside the prescribing decisions it records: evidence categories for off-label use, consent language for each compound class, monitoring schedules, and stop criteria, with patient cases. It is designated for up to 20 AMA PRA Category 1 Credits™. See the peptide course for physicians, or our guide to adding peptide therapy to your practice for the full launch sequence.
The indication and baseline findings, the contraindication screen, the product's approval status and source, a signed consent, the full prescription with the dose in mass units, a lot number for every dose given in the clinic, follow-up notes against the intake goal, any adverse events and reports, and the reason for every dose change or stop.
The course teaches one: a signed, dated form specific to off-label and compounded peptides. A general treatment consent rarely covers approval status, evidence limits, sourcing, or cost, which are the points a reviewer looks for.
Yes, for every dose given in the clinic and for every vial dispensed. Lot numbers are how a clinic finds the patients affected by a recall or a contamination report.
Units on an insulin syringe measure volume, so the same number of units holds a different amount of drug in each concentration. Recording micrograms or milligrams with the volume drawn makes the dose unambiguous.
Usually. The No Surprises Act requires a good faith estimate for uninsured and self-pay patients who schedule a service three or more business days ahead or ask for one, and it must be kept as part of the medical record.
To FDA's MedWatch program on Form 3500, marking the product as compounded, and to the dispensing pharmacy. Report even when you are unsure the peptide caused the event, and note both reports in the chart.
As long as your state requires for medical records, which varies by state and is longer for minors. Keep consent forms, administration logs, and good faith estimates with the chart for the same period.
